News from stemline therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 07, 2013, 08:30 ET

Stemline Therapeutics' Lead Clinical Candidate, SL-401, Induces Another Complete Response in a Patient with a Drug-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs)...

Dec 07, 2012, 08:30 ET
Nov 08, 2012, 08:30 ET

Stemline Therapeutics' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm

 Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells...

Apr 18, 2012, 08:00 ET
Apr 03, 2012, 07:30 ET

Stemline Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

 Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells...

Mar 15, 2012, 08:30 ET

Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors

 Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem...

Jan 09, 2012, 08:30 ET

Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development

 Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells...

Dec 12, 2011, 08:30 ET

Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference

 Stemline Therapeutics, Inc. today announced that Ivan Bergstein, MD, the Company's Chief Executive Officer, is scheduled to present at the...

Dec 08, 2011, 08:30 ET

Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)

 Stemline Therapeutics, Inc. today announced that two studies of SL-401, a clinical stage therapeutic being developed in patients with...

Jun 06, 2011, 08:00 ET

Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting

Stemline Therapeutics, Inc. today announced that clinical results from a multi-epitope brain cancer vaccine, that Stemline has licensed from the...

Mar 09, 2011, 08:30 ET

Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and...

Feb 23, 2011, 08:30 ET

Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs),...

Dec 01, 2010, 08:30 ET

Stemline Therapeutics, Inc. Announces Presentations of SL-401 Clinical and Pre-Clinical Efficacy at the 52nd Annual Meeting of the American Society of Hematology (ASH)

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and...

Dec 04, 2009, 08:30 ET

Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in...

Nov 30, 2009, 08:30 ET

Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center

Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer...

Jul 30, 2009, 08:30 ET

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell...

Apr 09, 2008, 01:00 ET

Stemline Therapeutics Raises $12.5 Million

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of...

Mar 07, 2007, 00:00 ET

Stemline Therapeutics In-Licenses Phase I Oncology Compound

NEW YORK, March 7 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that it has in-licensed the exclusive worldwide rights to SL-401,...

Jun 09, 2004, 01:00 ET

Xerion Pharmaceuticals and Stemline Therapeutics Announce Collaboration on Cancer Stem Cells

MUNICH, Germany and NEW YORK, June 9 /PRNewswire/ -- Xerion Pharmaceuticals AG and Stemline Therapeutics, Inc. have entered into a collaborative...